Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model

Journal of Alzheimer's Disease

Volumn 38, Issue 1, 2014, Pages 39-48

  Borghys, Herman ^a   Jacobs, Tom ^a   Van Broeck, Bianca ^a   Dillen, Lieve ^a   Dhuyvetter, Deborah ^a   Gijsen, Harrie ^a   Mercken, Marc ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Alzheimer's disease; amyloid peptides; cerebrospinal fluid; dog; secretase

Indexed keywords

ACETONITRILE; AMYLOID BETA PROTEIN[1-37]; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; GLYCOPROTEIN; JNJ A; JNJ B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANINE MODEL; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME INHIBITION; FEMALE; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PROCESSING; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ALZHEIMER'S DISEASE; AMYLOID-Β PEPTIDES; CEREBROSPINAL FLUID; DOG; Β-SECRETASE;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISTERNA MAGNA; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; IMMUNOASSAY; IMMUNOPRECIPITATION; LATERAL VENTRICLES; MALE; MODELS, ANIMAL; PEPTIDE FRAGMENTS; TANDEM MASS SPECTROMETRY;

EID: 84887257733     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130599     Document Type: Article

References (26)

1. Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol 68, 1-14.
2. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB (2003) Amyloid beta-protein (Afj) assembly: Afj40 and Afj42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100, 330-335. (Pubitemid 36078074)
3. Cole SL, Vassar R (2008) The role of amyloid precursor protein processing by BACE1, the fj-secretase, in Alzheimer disease pathophysiology. J Biol Chem 283, 29621-29625.
4. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698-712.
5. Borghys H, Tuefferd M, Van Broeck B, Clessens E, Dillen L, Cools W, Vinken P, Straetemans R, De Ridder F, Gijsen H, Mercken M (2012) A canine model to evaluate efficacy and safety of-y-secretase inhibitors and modulators. J Alzheimers Dis 28, 809-822.
6. Head E, Pop V, Sarsoza F, Kayed R, Beckett TL, Studzinski CM, Tomi JL, Glabe CG, Murphy MP (2010) Amyloid fj-peptide and oligomers in the brain and CSF of aged canines. J Alzheimers Dis 20, 637-646.
7. Cotman CW, Head E (2008) The canine (dog) model of human aging and disease: Dietary, environmental and immunotherapy approaches. J Alzheimers Dis 15, 685-707.
8. Studzinski CM, Araujo JA, Milgram NW (2005) The canine model of human cognitive aging and dementia: Pharmacological validity of the model for assessment of human cognitive-enhancing drugs. Prog Neuropsychophar-macol Biol Psychiatry 29, 489-498. (Pubitemid 40417601)
9. Sarasa L, Gallego C, Monleon I, Olvera A, Canudas J, Mon-tanes M, Pesini P, Sarasa M (2010) Cloning, sequencing and expression in the dog of the main amyloid precursor protein isoforms and some of the enzymes related with their processing. Neuroscience 171, 1091-1101.
10. Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K (2010) Acute effect on the Afj isoform pattern in CSF in response to-y-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 21, 1005-1012.
11. Lu Y, Barton HA, Leung L, Zhang L, Hajos-Korcsok E, Nolan CE, Liu J, Becker SL, Wood KM, Robshaw AE, Taylor CK, O'Neill BT, Brodney MA, Riddel D (2013) Cerebrospinal fluid fj-amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses. Neu-rodegener Dis 12, 36-50.
12. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, Andreasen N, Zetterberg H, Andreasson U, Blennow K (2010) Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010, pii: 986310.
13. Dillen L, Cools W, Vereyken L, Timmerman P (2011) A screening UPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species. Bioanalysis 3, 45-55.
14. Goda R, Kobayashi N (2012) Evaluation of peptide adsorption-controlled liquid chromatography-tandem mass spectrometric (PAC-LC-MS/MS) method for simple and simultaneous quantitation of amyloid beta 1-38, 1-40, 1-42 and 1-43 peptides in dog cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 895-896, 137-145.
15. Slemmon JR, Meredith J, Guss V, Anreasson U, Andreasen N, Zetterberg H, Blennow K (2011) Measurement of Afj 1-42 in cerebrospinal fluid is influenced by matrix effects. J Neu-rochem 120, 325-333.
16. Dhuyvetter D, Borghys H, Van Broeck B, Dillen L, Gijsen H, Jacobs T, Steckler T (2012) Evaluation and comparison of BACE-1-inhibitors in a canine PK/PD model. Soc Neurosci Abstr, Poster #343. 08/G17.
17. Trabanco-Suarez A, Rombouts F, Tresaderm G, Van Gool M, Macdonald G, Martinez Lamenca C, Gijsen H (2011) Preparation of 5, 6-dihydro-2H-[1, 4]oxazin-3-yl-amine derivatives useful as therapeutic inhibitors of fj-secretase (BACE). PCT Int Appl, WO 2011-154431.
18. Wilsson-Rahmber M, Olovson SG, Forshult E (1998) Method for long-term cerebrospinal fluid collection in the conscious dog. J Invest Surg 11, 207-214. (Pubitemid 28425423)
19. Gabrielson J, Weiner D (2001) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Swedish Pharmaceutical Press, Stockholm.
20. de Lahunta A (1977) Veterinary Neuroanatomy and Clinical Neurology, Saunders, St. Louis.
21. Battal B, Kocaoglu M, Bulakbasi N, Husmen G, Tuba Sanal H, Tayfun C (2011) Cerebrospinal fluid flow imaging by using phase-contrast MR technique. Br J Radiol 84, 758-765.
22. Crossgrove JS, Smith EL, Zheng W (2007) Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers. Brain Res 1138, 187-195. (Pubitemid 46281881)
23. Crossgrove J, Li JG, Zheng W (2005) The choroid plexus removes fj-amyloid from brain cerebrospinal fluid. Exp Biol Med 230, 771-776. (Pubitemid 41565947)
24. Finder VH, Glockshuber R (2007) Amyloid-fj aggregation. Neurodegener Dis 4, 13-27.
25. Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, Hojrup P, Minthon L, Hansson O, Zetterberg H, Blennow K, Gobom J (2013) A selected reaction monitoring (SRM)-based method for absolute quantification of Afj38, Afj40 and Afj42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J Alzheimers Dis 33, 1021-1032.
26. Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, Pietrak B, Price EA, Rajapakse H, Stauf-fer S, Steinbeiser MA, Seabrook G, Selnick HG, Shi XP, Stanton MG, Swestock J, Tugusheva K, Tyler KX, Vacca JP, Wong J, Wu G, Xu M, Cook JJ, Simon AJ (2009) First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 328, 131-140.